Sera Prognostics, Inc. (NASDAQ:SERA) Short Interest Update

Key Points

• Sera Prognostics experienced a significant decline in short interest, dropping by 34.0% from 1,240,000 shares in July to 817,900 shares by August 15th.
• The company's stock closed at $3.34 on Friday, with a market capitalization of $125.82 million and a PE ratio of -3.93.
• Recent earnings showed a loss of ($0.16) EPS, exceeding expectations, but with a negative return on equity of 45.86% and net margin of 30,306.48%.

Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) was the recipient of a large drop in short interest in August. As of August 15th, there was short interest totaling 817,900 shares, adropof34.0% from the July 31st total of 1,240,000 shares. Based on an average trading volume of 370,900 shares, the short-interest ratio is presently 2.2 days. Approximately3.3% of the shares of the stock are short sold. Approximately3.3% of the shares of the stock are short sold. Based on an average trading volume of 370,900 shares, the short-interest ratio is presently 2.2 days.

Sera Prognostics Stock Performance

SERA traded down $0.07 on Friday, hitting $3.34. 76,225 shares of the company were exchanged, compared to its average volume of 119,741. The firm has a fifty day simple moving average of $2.76 and a two-hundred day simple moving average of $2.89. Sera Prognostics has a 12 month low of $1.37 and a 12 month high of $9.13. The stock has a market capitalization of $125.82 million, a PE ratio of -3.93 and a beta of 1.00.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.05. Sera Prognostics had a negative return on equity of 45.86% and a negative net margin of 30,306.48%.The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.05 million. On average, equities analysts expect that Sera Prognostics will post -0.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen downgraded Sera Prognostics from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th.

Insider Buying and Selling at Sera Prognostics

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 23,042 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $1.43, for a total value of $32,950.06. Following the sale, the chief executive officer owned 844,209 shares of the company's stock, valued at $1,207,218.87. This trade represents a 2.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last 90 days, insiders sold 45,587 shares of company stock valued at $74,251. Company insiders own 13.50% of the company's stock.

Hedge Funds Weigh In On Sera Prognostics

Several institutional investors and hedge funds have recently bought and sold shares of SERA. BNP Paribas Financial Markets purchased a new position in shares of Sera Prognostics during the fourth quarter valued at approximately $28,000. Abel Hall LLC purchased a new position in shares of Sera Prognostics during the second quarter valued at approximately $31,000. Wagner Wealth Management LLC purchased a new position in shares of Sera Prognostics during the second quarter valued at approximately $34,000. Riverview Capital Advisers LLC purchased a new position in shares of Sera Prognostics during the second quarter valued at approximately $35,000. Finally, XTX Topco Ltd purchased a new position in shares of Sera Prognostics during the first quarter valued at approximately $39,000. 54.64% of the stock is currently owned by institutional investors.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.